Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | June 18, 2025 | June 23, 2025 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIMEDX GROUP, INC.
Report date June 18, 2025 · Filed June 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,771 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 28,609 · Balance 212,771 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,357 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 214,357 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 10,000 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IGM Biosciences, Inc.
Report date August 14, 2025 · Filed August 14, 2025
Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-14 transaction · row 1
1 source rowRow 1 · 2025-08-14 · Disposition to issuer · Disposed 22,222 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-14 · Disposition to issuer · Disposed 330,700 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F2: Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-08-14 · Disposition to issuer · Disposed 29,807 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F3: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2025-08-14 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-08-14 · Disposition to issuer · Disposed 29,806 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F4: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.
F2: Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee.
F3: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
F4: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 6, 2026 00:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-260257 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,357 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001193125-26-029893 · ownership.xml · derivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 6,494 | $22.17 | $143,971.98 |
DisclosureSEC source: 0001193125-26-029893 · ownership.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,482 F1 · kind: Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not withheld by the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,500 | $13.71 | $143,955.00 |
DisclosureSEC source: 0001193125-26-029893 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 17:17 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerCommon Stock | 29,806 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021950 · form4-08142025_090828.xml · nonDerivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F4 · ownership.nature: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 17:17 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerCommon Stock | 29,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021950 · form4-08142025_090828.xml · nonDerivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F3 · ownership.nature: Prior to the Merger, the shares were held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 17:17 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerCommon Stock | 330,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021950 · form4-08142025_090828.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F2 · ownership.nature: Prior to the Merger, the shares were held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 17:17 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerCommon Stock | 22,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021950 · form4-08142025_090828.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 18:51 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019152 · form4-07022025_100759.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,222 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:42 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 28,609 | $6.47 | $185,100.23 |
DisclosureSEC source: 0001376339-25-000072 · wk-form4_1750718569.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,771 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:00 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009777 · form4-04022025_110435.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,751 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 4,792 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037511 · ownership.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires 2035-03-10 Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037511 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,476 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 17:54 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 3,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000608 · form4-01032025_100158.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,280 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 19:58 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 3,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024533 · form4-10022024_111005.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,202 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GiftCommon Stock | 746 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-104194 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,093 F1 · price: Represents a charitable gift by the Reporting Person. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0000950170-24-082240 · ownership.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 15,000 | $13.90 | $208,500.00 |
DisclosureSEC source: 0000950170-24-082240 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:06 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 3,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019056 · form4-07032024_120717.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,124 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 20:18 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 23,190 | $7.26 | $168,359.40 |
DisclosureSEC source: 0001376339-24-000047 · wk-form4_1717705117.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,162 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 18:22 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 3,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009849 · form4-04022024_100447.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,046 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 17:50 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 29,400 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-24-008027 · form4-03142024_090318.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2034-03-12 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2024 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,679 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026618 · ownership.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 3,679 shares Expires 2034-03-01 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026618 · ownership.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,839 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 18:14 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000520 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,968 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-23-054440 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 13:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 15,000 | $29.03 | $435,450.00 |
DisclosureSEC source: 0001209191-23-054440 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 19:50 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051739 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,168 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:05 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041386 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 19:34 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 112,500 | $8.00 | $900,000.00 |
DisclosureSEC source: 0001209191-23-040091 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 330,700 F1 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F2 · ownership.nature: The shares are held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:20 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 35,354 | $4.95 | $175,002.30 |
DisclosureSEC source: 0001376339-23-000041 · wk-form4_1686867605.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,972 F1 · shares: Represents annual restricted stock unit grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:36 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 15,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001209191-23-023694 · doc4.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2033-04-04 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2023 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022973 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,568 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,257 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017402 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2033-03-06 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017402 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,993 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 17:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001103 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,768 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 14:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-22-062287 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 14:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 20,000 | $34.92 | $698,400.00 |
DisclosureSEC source: 0001209191-22-062287 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 17:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 60,000 | $17.14 | $1,028,550.00 |
DisclosureSEC source: 0001209191-22-056423 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 218,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $16.94 to $17.25. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price. F2 · ownership.nature: The shares are held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:12 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051985 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,394 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 18:14 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-040886 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,020 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 13, 2022 22:28 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 44,191 | $3.96 | $174,996.36 |
DisclosureSEC source: 0001376339-22-000089 · wf-form4_165515928060630.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,618 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 8,695 | $23.00 | $199,985.00 |
DisclosureSEC source: 0001209191-22-022716 · doc4.xml · nonDerivative · entry 4 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 29,806 F2 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F5 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 8,696 | $23.00 | $200,008.00 |
DisclosureSEC source: 0001209191-22-022716 · doc4.xml · nonDerivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 29,807 F2 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F4 · ownership.nature: The shares are held in the name of Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust for which Reporting Person is a Trustee. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | PurchaseCommon Stock | 43,478 | $23.00 | $999,994.00 |
DisclosureSEC source: 0001209191-22-022716 · doc4.xml · nonDerivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 158,200 F2 · kind: The shares were purchased pursuant to an underwritten public offering of the Issuer's securities. F3 · ownership.nature: The shares are held in the name of KBW 2005 Trust for which Reporting Person is the Trustee. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 374 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022716 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:55 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 29,497 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-22-019015 · doc4.xml · derivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 Underlying: Common Stock · 29,497 shares Expires 2032-03-12 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2022 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,077 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017349 · doc4.xml · derivative · entry 3 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 Underlying: Common Stock · 5,077 shares Expires 2032-03-07 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017349 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,470 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 7, 2023. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:04 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001216 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,272 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.